探索对严重喘生物药物反应的定义和预测因素
Ghislaine Scelo1, Trung N Tran2, Tham T Le2
1Observational and Pragmatic Research Institute, Singapore; Optimum Patient Care Global, Cambridge, United Kingdom.
概括
在严重喘中定义生物反应是复杂的. 许多患者在治疗后仍然有症状,预测因结果而异.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 生物疗法的有效性通常以反应来衡量,但一致的定义仍然难以捉摸.
- 在现实环境中确定最有可能从生物制剂中受益的患者是具有挑战性的.
研究的目的:
- 在患有严重喘的成年人中定义生物反应者.
- 为了研究与严重喘中的生物反应相关的患者特征.
主要方法:
- 一项纵向队列研究分析了来自国际严重喘登记 (21个国家) 的数据.
- 在生物启动1年后评估恶化率,口服皮质类固醇剂量,喘控制和FEV1 (肺功能) 的变化.
- 根据单个或多个结果领域定义的响应者,并使用多变量分析分析了响应的预生物学预测因素.
主要成果:
- 响应率有显著的变化,从80.7%的恶化到10.6%的四域响应.
- 许多被定义为响应患者的患者在治疗后仍然有显著的喘损伤.
- 响应的预测因素是结果特异性的;例如,更高的FeNO和更短的喘持续时间预测了肺功能响应,而血液中乙氨基酸细胞数量和2型并发症预测了其他响应类型.
结论:
- 严重喘的生物反应是多模式和复杂的.
- 显著比例的响应者经历残留症状,突出需要量身定制的治疗方法.
- 生物反应的预测因评估的具体结果而异,强调全面评估的重要性.
相关概念视频
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management
388
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
388
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
273
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
273
Antiasthma Drugs: β2-Adrenoceptor Agonists
250
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
250
Drugs Used in Lower Respiratory Disorders: Overview
421
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
421
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


